Aclaris Therapeutics (ACRS) Stock Price, Quote, News & History | Benzinga

Comments

Aclaris Therapeutics Inc (ACRS) Stock Price, Quote, News & History

ACRSNASDAQ

Trade with Public

Trade with Public

$3.19

-0.17-5.06%

At close: Feb 13, 4:00 PM EST

$3.19

N/A

After Hours: Feb 13, 4:00 PM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$3.36

Close

$3.19

Volume / Avg.

783.46K / 1.79M

Day Range

$3.17 - $3.40

52 Wk Range

1.05 - 4.89

Market Cap

$345.62M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

5.49%

Days to Cover

1

Recent Aclaris Therapeutics Inc News

Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.

Vandana Singh

Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus

U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indices were slightly higher.

Rishabh Mishra

Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement

Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from its open-label Phase 2a trial.

Mohd Haider

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-42.92M

Investing Cash Flow (TTM)

-50.73M

Financing Cash Flow (TTM)

71.25M

Free Cash Flow (TTM)

-78.82M

Capital Expenditure (TTM)

-35.90M

Net Change in Cash (TTM)

-22.40M

Analyst Trends and Forecast

1

Oct 25

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$268.11M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

24.78

PB Ratio (TTM)

3.04

Earnings Yield % (TTM)

-46.88%

Earnings Yield % (FWD)

-15.73%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.11

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$25.26M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.36

Close

$3.19

Volume / Avg.

783.46K / 1.79M

Day Range

$3.17 - $3.40

52 Wk Range

1.05 - 4.89

Market Cap

$345.62M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

5.49%

Days to Cover

1

About

Sector

Health Care

Industry

Pharmaceuticals

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Aclaris Therapeutics (ACRS) stock?

A

You can purchase shares of Aclaris Therapeutics (NASDAQ:ACRS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Aclaris Therapeutics (ACRS) competitors?

A

Other companies in Aclaris Therapeutics’s space includes: Atea Pharmaceuticals Inc (NASDAQ:AVIR), MediWound Ltd (NASDAQ:MDWD), Zevra Therapeutics Inc (NASDAQ:ZVRA), SNDL Inc (NASDAQ:SNDL) and NervGen Pharma Corp (NASDAQ:NGEN).

Q

What is the forecast, or price target, for Aclaris Therapeutics (ACRS) stock?

A

Aclaris Therapeutics has a consensus price target of $10.73.

Q

What is the current price for Aclaris Therapeutics (ACRS)?

A

The stock price for Aclaris Therapeutics (NASDAQ: ACRS) is $3.19 last updated February 13, 2026 at 4:00 PM EST.

Q

Does Aclaris Therapeutics (ACRS) pay a dividend?

A

There are no upcoming dividends for Aclaris Therapeutics.

Q

When is Aclaris Therapeutics (NASDAQ:ACRS) reporting earnings?

A

Aclaris Therapeutics does not have any upcoming earnings scheduled.

Q

Is Aclaris Therapeutics (ACRS) going to split?

A

There is no upcoming split for Aclaris Therapeutics.

Q

What sector and industry does Aclaris Therapeutics (ACRS) operate in?

A

Aclaris Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Atea Pharmaceuticals Inc

Zevra Therapeutics Inc

NervGen Pharma Corp

Neumora Therapeutics Inc

Aardvark Therapeutics Inc

Aquestive Therapeutics Inc